The combined effect of topical CX-659S, a novel diaminouracil derivative, with topical corticosteroid on the three types of allergic responses in mice or guinea pigs

Journal Pharmacological Sciences

Volumn 91, Issue 1, 2003, Pages 71-78

  Inoue, Yoshifumi ^a   Isobe, Masakazu ^a   Hayashi, Hideya ^a  

^a JAPAN ENERGY CORPORATION   (Japan)

Author keywords

Combined effect; Corticosteroid; CX 659S; Th1 type reaction; Th2 type reaction

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 6 AMINO 5 (6 HYDROXY 2,5,7,8 TETRAMETHYLCHROMAN 2 CARBOXYAMIDO) 3 METHYL 1 PHENYL 2,4(1H,3H)PYRIMIDINEDIONE; ANTIINFLAMMATORY AGENT; BETAMETHASONE VALERATE; CORTICOSTEROID; CX 659S; OVALBUMIN; OXAZOLONE; PICRYL CHLORIDE; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GUINEA PIG; IMMEDIATE TYPE HYPERSENSITIVITY; MALE; MOUSE; NONHUMAN; TH1 CELL; TH2 CELL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETAMETHASONE 17-VALERATE; DERMATITIS, CONTACT; DINITROCHLOROBENZENE; GUINEA PIGS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; INDICATORS AND REAGENTS; IRRITANTS; MICE; MICE, INBRED ICR; OVALBUMIN; SKIN; URACIL;

EID: 0038392743     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.91.71     Document Type: Article

References (44)

1. Cooper KD: Atopic dermatitis: Recent trends in pathogenesis and therapy. J Invest Dermatol 102, 128-137 (1994)
2. Thestrup-Pedersen K: Clinical aspects of atopic dermatitis. Clin Exp Dermatol 25, 535-543 (2000)
3. Inagaki N and Nagai H: Drugs for the treatment of allergic disease. Jpn J Pharmacol 86, 275-280 (2001)
4. Charma CR, Morris AD and Williams HC: Topical corticosteroid phobia in patients with eczema. Br J Dermatol 142, 931-936 (2000)
5. Hanifin JM: Atopic dermatitis: New therapeutic considerations. J Am Acad Dermatol 24, 1097-1101 (1991)
6. Lesnik RH, Mezick JA, Capetola R and Klibman LH: Topical all-trans retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 21, 186-190 (1989)
7. Oshima Y and Puri RK: Characterization of a powerful high affinity antagonists that inhibits biological activities of human interleukin-13. J Biol Chem 276, 15185-15191 (2001)
8. Elsner J, Petering H, Kimmin D, Wells TN, Proudfoot AE and Kapp A: The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 118, 462-465 (1999)
9. Schachner LA: A 3-day rate of efficacy of a moderate potency topical steroid in the treatment of atopic dermatitis in infancy and childhood. Pediatr Dermatol 13, 513-514 (1996)
10. Williams RE: The antibacterial-corticosteroid combination. What is its role in atopic dermatitis? Am J Clin Dermatol 1, 211-215 (2000)
11. Niwa Y, Tominaga K and Yoshida K: Successful treatment of severe atopic dermatitis-complicated cataract and male infertility with a natural product antioxidant. Int J Tissue React 20, 63-69 (1998)
12. Goto Y, Inoue Y, Tsuchiya M, Isobe M, Ueno T, Uchi H, Furue M and Hayashi H: Suppressive effect of topically applied CX-659S, a novel diaminouracil derivative, on the contact hypersensitivity reaction in various animal models. Int Arch Allergy Immunol 123, 341-348 (2000)
13. Inoue Y, Isobe M, Shiohara T, Goto Y and Hayashi H: Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses. Br J Dermatol 147, 675-682 (2002)
14. Kitagaki H, Fujisawa S, Watanabe K, Hayakawa K and Shiohara T: Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J Invest Dermatol 105, 749-755 (1995)
15. Kitagaki H, Ono N, Hayakawa K, Kitazawa T, Watanabe K and Shiohara T: Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol 159, 2484-2491 (1997)
16. Kitagaki H, Kimishima M, Teraki Y, Hayakawa J, Hayakawa K, Fujisawa S and Shiohara T: Distinct in vivo and in vitro cytokine profiles of draining lymph node cells in acute and chronic phases of contact hypersensitivity: Importance of a type 2 cytokine-rich cutaneous milieu for the development of an early-type response in the chronic phase. J Immunol 163, 1265-1273 (1999)
17. Goto Y, Watanabe N, Kogawa N, Tsuchiya M, Takahashi O, Uchi H, Furue M and Hayashi H: CX-659S: A novel diaminouracil derivative that has antioxidative and acute anti-inflammatory activities. Eur J Pharmacol 438, 186-196 (2002)
18. Tobe M, Isobe Y, Goto Y, Obara F, Tsuchiya M, Matsui J, Hirota K and Hayashi H: Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction. Bioorg Med Chem 8, 2037-2047 (2000)
19. Grewe M, Gyufko K, Schöpf E and Krutmann J: Lesional expression of interferon-γ in atopic eczema. Lancet 343, 25-26 (1994)
20. Grewe M, Walther S, Gyufko K, Czech W, Schöpf E and Krutmann J: Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 105, 407-410 (1995)
21. Grewe M, Bruijnzeel-Koomen CAFM, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T and Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 19, 359-361 (1998)
22. Hamid Q, Boguniewicz M and Leung DYM: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94, 870-876 (1994)
23. Yamada N, Wakugawa M, Kuwata S, Yoshida T and Nakagawa H: Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. J Allergy Clin Immunol 96, 1069-1075 (1995)
24. H1 response in situ: An immunocytochemical study. J Allergy Clin Immunol 97, 828-837 (1996)
25. Werfel T, Morita A, Grewe M, Renz H, Wahn U, Krutmann J and Kapp A: Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 107, 871-876 (1996)
26. Gaga M, Frew AJ, Varney VA and Kay AB: Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol 147, 816-822 (1991)
27. Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J and Bienenstock J: Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 52, 38-46 (1973)
28. Warner JA, Pienkowski MM, Plaut M, Norman PS and Lichtenstein LM: Identification of histamine releasing factor(s) in the late phase of cutaneous IgE-mediated reactions. J Immunol 136, 2583-2587 (1986)
29. Kapsenberg ML, Jansen HM, Bos JD and Wierenga EA: Role of type 1 and type 2 T helper cells in allergic diseases. Curr Opin Immunol 4, 788-793 (1992)
30. Iwamoto I, Tomoe S, Tomioka H, Takatsu K and Yoshida S: Role of CD4+ T lymphocytes and interleukin-5 in antigen-induced eosinophil recruitment into the site of cutaneous late-phase reaction in mice. J Leukoc Biol 52, 572-578 (1992)
31. Gordon JR, Burd PR and Galli SJ: Mast cells as a source of multifunctional cytokines. Immunol Today 11, 458-464 (1990)
32. Seder RA, Paul WE, Ben-Sasson SZ, LeCros GS, Kagey-Sobotka A, Finkelman FD, Pierce JH and Plaut M: Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils. Int Archs Allergy Appl Immunol 94, 137-140 (1991)
33. Sawada K, Nagai H, Basaki Y, Yamaya H, Ikizawa K, Watanabe M, Kojima M, Matsuura N and Kiniwa M: The expression of murine cutaneous late phase reaction requires both IgE antibodies and CD4 T cells. Clin Exp Allergy 27, 225-231 (1996)
34. Togawa M, Kiniwa M and Nagai H: The roles of IL-4, IL-5 and mast cells in the accumulation of eosinophils during allergic cutaneous late phase reaction in mice. Life Sci 69, 699-705 (2001)
35. Sengoku T, Morita K, Sato S, Sakuma S, Ogawa T, Hiroi J, Fujii T and Goto T: Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice. Folia Pharmacol Jpn (Nippon Yakaurigaku Zasshi) 112, 221-232 (1998) (text in Japanese with English abstract)
36. Rice-Evans CA and Diplock AT: Current status of antioxidant therapy. Free Radical Biol Med 15, 77-96 (1993)
37. Das UN, Vijaykumavan K, Madhavi N, Suryaprabha P, Sravan-Kumar G, Ramesh G, Koratkar R, Sagar PS and Padma M: Psoriasis: Current concepts and new approaches to therapy. Med Hypotheses 38, 56-62 (1992)
38. Muller K: Antipsoriatic and proinflammatory action of anthralin: Implications for the role of oxygen radicals. Biochem Pharmacol 53, 1215-1221 (1997)
39. Polla PS, Ezekowitz RA and Leung DYM: Monocytes from patients with atopic dermatitis are primed for superoxide production. J Allergy Clin Immunol 89, 545-551 (1992)
40. Sharkey P, Eedy DJ, Burrows D, McCaigue MD and Bell AL: A possible role for superoxide production in the pathogenesis of contact dermatitis. Acta Derm-Venereol 71, 156-159 (1991)
41. Schwiebert LM, Beck LA, Atellato C, Bickel CA, Bochner BS and Schleimer RP: Glucocorticosteroid inhibition of cytokine production: Relevance to antiallergic actions. J Allergy Clin Immunol 97, 143-152 (1996)
42. Barnes PJ: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 94, 557-572 (1998)
43. Nakano T, Ohara O, Teraoka H and Arita H: Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 265, 12745-12748 (1990)
44. Masferrer JL, Zweifel BS, Seibert K and Needleman P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86, 1375-1379 (1990)